167 related articles for article (PubMed ID: 24607004)
1. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB
Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
9. Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.
Tree JA; Hall G; Rees P; Vipond J; Funnell SG; Roberts AD
Hum Vaccin Immunother; 2016 Jul; 12(7):1795-801. PubMed ID: 26836234
[TBL] [Abstract][Full Text] [Related]
10. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.
Troy JD; Hill HR; Ewell MG; Frey SE
Vaccine; 2015 Oct; 33(41):5425-5431. PubMed ID: 26319063
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A; Vollmar J; Pokorny R; Rapp P; Wulff N; Petzold B; Handley A; Mateo L; Siersbol H; Kollaritsch H; Chaplin P
Vaccine; 2010 Feb; 28(5):1209-16. PubMed ID: 19944151
[TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
Kennedy JS; Gurwith M; Dekker CL; Frey SE; Edwards KM; Kenner J; Lock M; Empig C; Morikawa S; Saijo M; Yokote H; Karem K; Damon I; Perlroth M; Greenberg RN
J Infect Dis; 2011 Nov; 204(9):1395-402. PubMed ID: 21921208
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent neutralizing-antibody responses to vaccinia.
Belshe RB; Newman FK; Frey SE; Couch RB; Treanor JJ; Tacket CO; Yan L
J Infect Dis; 2004 Feb; 189(3):493-7. PubMed ID: 14745707
[TBL] [Abstract][Full Text] [Related]
16. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
Ilchmann H; Samy N; Reichhardt D; Schmidt D; Powell JD; Meyer TPH; Silbernagl G; Nichols R; Weidenthaler H; De Moerlooze L; Chen L; Chaplin P
J Infect Dis; 2023 May; 227(10):1203-1213. PubMed ID: 36408618
[TBL] [Abstract][Full Text] [Related]
17. Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.
Hughes CM; Newman FK; Davidson WB; Olson VA; Smith SK; Holman RC; Yan L; Frey SE; Belshe RB; Karem KL; Damon IK
Clin Vaccine Immunol; 2012 Jul; 19(7):1116-8. PubMed ID: 22593237
[TBL] [Abstract][Full Text] [Related]
18. Duration of neutralizing antibody persisting in Thai individuals after childhood vaccination against smallpox.
Kwanchum K; Ampol S; Thongput A; Horthongkham N; Udomphunthurak S; Siritantikorn S; Kantakamalakul W
Asian Pac J Allergy Immunol; 2017 Dec; 35(4):239-243. PubMed ID: 28577520
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
